Obesity Discussions to Take Spotlight at RSSDI 2025; Experts to Delve into Tirzepatide's Dual Agonism in Metabolic Care Deeksha Bhandari4 Nov 2025 12:20 PM ISTThe topic of obesity and metabolic disease will take centre stage at the upcoming 53rd Annual Conference of the Research Society for the Study of...
Explainer video: Assess- Evaluating Patient Readiness for Diabetes- Management Strategies Deeksha Bhandari31 Oct 2025 12:01 PM ISTDiscussing weight with people living with type 2 diabetes can be difficult, but it is vital to improving care. Many patients with overweight or...
Eli Lilly's Diabetes Drug Mounjaro Gets Second Brand Yurpeak via Cipla Deal Farhat Nasim24 Oct 2025 11:36 AM ISTNew Delhi: In a move aimed at expanding access to obesity and diabetes care in India, Eli Lilly and Company (India) Pvt. Ltd. (Lilly) and Cipla...
CDSCO Panel Clears Eli Lilly's Tirzepatide for Phase IV Clinical Trial in India Susmita Roy21 Oct 2025 12:30 PM ISTNew Delhi: The Subject Expert Committee (SEC), functioning under the Central Drugs Standard Control Organisation (CDSCO), has granted permission to...
Rs 233 Crore in 6 Months: Mounjaro Becomes India's Second-Biggest Drug by Sales Farhat Nasim10 Oct 2025 3:46 PM ISTNew Delhi: In a remarkable rise, Eli Lilly's Mounjaro (tirzepatide) has become India's second-highest selling drug by value within just six months of...
New EASO guidance recommends semaglutide and tirzepatide as first-line treatments for obesity and its major complications Dr. Kamal Kant Kohli6 Oct 2025 8:30 AM ISTSemaglutide or tirzepatide should be the first line treatment for people living with obesity and most of its complications, according to a new...
Tirzepatide Improved Outcomes in Patients with Both Atrial Fibrillation and COPD: Study Jacinthlyn Sylvia4 Oct 2025 9:00 AM ISTA new study published in The American Journal of Medicine found tirzepatide, which is prescribed for diabetes and weight management, to significantly...
Tirzepatide proves to be more effective than semaglutide- Results of Surmount 5 Trial Deeksha Bhandari3 Oct 2025 12:09 PM ISTSURMOUNT-5 was a 72-week, Phase 3b, multicenter, randomized, open-label, comparator-controlled study that evaluated the efficacy and safety of...
Tirzepatide Improves Blood Sugar Control in Children With Type 2 Diabetes: SURPASS-PEDS Trial Dr. Kamal Kant Kohli20 Sept 2025 9:00 AM ISTNew research shows that that the diabetes/obesity medication tirzepatide can cause clinically meaningful improvements in blood sugar control and...
Tirzepatide and Thiazide Use in CKD Linked to Risk of Severe Hypercalcemia, Reveals Case Report Medha Baranwal16 Sept 2025 8:45 PM ISTUSA: Researchers have reported a potential risk of severe hypercalcemia when tirzepatide, a dual GIP and GLP-1 receptor agonist, is used in...
Tirzepatide- A novel therapeutic against metabolic dysfunction-associated steatotic liver disease, reports research Dr. Kamal Kant Kohli13 Sept 2025 9:15 AM ISTMetabolic dysfunction-associated steatohepatitis (MASLD) is a liver disease with complex pathogenesis, characterized by abnormal lipid accumulation...
EMA warns of sharp rise in illegal medicines sold in EU Ruchika Sharma8 Sept 2025 2:18 PM ISTEuropean Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) are warning the public about the growing threat of illegal medicines being...
